• Home
  • About RSIS
    • Introduction
    • Building the Foundations
    • Welcome Message
    • Board of Governors
    • Staff Profiles
      • Executive Deputy Chairman’s Office
      • Dean’s Office
      • Management
      • Distinguished Fellows
      • Faculty and Research
      • Associate Research Fellows, Senior Analysts and Research Analysts
      • Visiting Fellows
      • Adjunct Fellows
      • Administrative Staff
    • Honours and Awards for RSIS Staff and Students
    • RSIS Endowment Fund
    • Endowed Professorships
    • Career Opportunities
    • Getting to RSIS
  • Research
    • Research Centres
      • Centre for Multilateralism Studies (CMS)
      • Centre for Non-Traditional Security Studies (NTS Centre)
      • Centre of Excellence for National Security (CENS)
      • Institute of Defence and Strategic Studies (IDSS)
      • International Centre for Political Violence and Terrorism Research (ICPVTR)
    • Research Programmes
      • National Security Studies Programme (NSSP)
      • Studies in Inter-Religious Relations in Plural Societies (SRP) Programme
    • Future Issues and Technology Cluster
    • [email protected] Newsletter
    • Other Research
      • Science and Technology Studies Programme (STSP) (2017-2020)
  • Graduate Education
    • Graduate Programmes Office
    • Overview
    • MSc (Asian Studies)
    • MSc (International Political Economy)
    • MSc (International Relations)
    • MSc (Strategic Studies)
    • NTU-Warwick Double Masters Programme
    • PhD Programme
    • Exchange Partners and Programmes
    • How to Apply
    • Financial Assistance
    • Meet the Admissions Team: Information Sessions and other events
    • RSIS Alumni
  • Alumni & Networks
    • Alumni
    • Asia-Pacific Programme for Senior Military Officers (APPSMO)
    • Asia-Pacific Programme for Senior National Security Officers (APPSNO)
    • International Strategy Forum-Asia (ISF-Asia)
    • SRP Executive Programme
    • Terrorism Analyst Training Course (TATC)
  • Publications
    • RSIS Publications
      • Annual Reviews
      • Books
      • Bulletins and Newsletters
      • Commentaries
      • Counter Terrorist Trends and Analyses
      • Commemorative / Event Reports
      • IDSS Paper
      • Interreligious Relations
      • Monographs
      • NTS Insight
      • Policy Reports
      • Working Papers
      • RSIS Publications for the Year
    • Glossary of Abbreviations
    • External Publications
      • Authored Books
      • Journal Articles
      • Edited Books
      • Chapters in Edited Books
      • Policy Reports
      • Working Papers
      • Op-Eds
      • External Publications for the Year
    • Policy-relevant Articles Given RSIS Award
  • Media
    • Great Powers
    • Sustainable Security
    • Other Resource Pages
    • Media Highlights
    • News Releases
    • Speeches
    • Vidcast Channel
    • Audio/Video Forums
  • Events
  • Giving
  • Contact Us
Facebook
Twitter
YouTube
RSISVideoCast RSISVideoCast rsis.sg
Linkedin
instagram instagram rsis.sg
RSS
  • Home
  • About RSIS
      • Introduction
      • Building the Foundations
      • Welcome Message
      • Board of Governors
      • Staff Profiles
        • Executive Deputy Chairman’s Office
        • Dean’s Office
        • Management
        • Distinguished Fellows
        • Faculty and Research
        • Associate Research Fellows, Senior Analysts and Research Analysts
        • Visiting Fellows
        • Adjunct Fellows
        • Administrative Staff
      • Honours and Awards for RSIS Staff and Students
      • RSIS Endowment Fund
      • Endowed Professorships
      • Career Opportunities
      • Getting to RSIS
  • Research
      • Research Centres
        • Centre for Multilateralism Studies (CMS)
        • Centre for Non-Traditional Security Studies (NTS Centre)
        • Centre of Excellence for National Security (CENS)
        • Institute of Defence and Strategic Studies (IDSS)
        • International Centre for Political Violence and Terrorism Research (ICPVTR)
      • Research Programmes
        • National Security Studies Programme (NSSP)
        • Studies in Inter-Religious Relations in Plural Societies (SRP) Programme
      • Future Issues and Technology Cluster
      • [email protected] Newsletter
      • Other Research
        • Science and Technology Studies Programme (STSP) (2017-2020)
  • Graduate Education
      • Graduate Programmes Office
      • Overview
      • MSc (Asian Studies)
      • MSc (International Political Economy)
      • MSc (International Relations)
      • MSc (Strategic Studies)
      • NTU-Warwick Double Masters Programme
      • PhD Programme
      • Exchange Partners and Programmes
      • How to Apply
      • Financial Assistance
      • Meet the Admissions Team: Information Sessions and other events
      • RSIS Alumni
  • Alumni & Networks
      • Alumni
      • Asia-Pacific Programme for Senior Military Officers (APPSMO)
      • Asia-Pacific Programme for Senior National Security Officers (APPSNO)
      • International Strategy Forum-Asia (ISF-Asia)
      • SRP Executive Programme
      • Terrorism Analyst Training Course (TATC)
  • Publications
      • RSIS Publications
        • Annual Reviews
        • Books
        • Bulletins and Newsletters
        • Commentaries
        • Counter Terrorist Trends and Analyses
        • Commemorative / Event Reports
        • IDSS Paper
        • Interreligious Relations
        • Monographs
        • NTS Insight
        • Policy Reports
        • Working Papers
        • RSIS Publications for the Year
      • Glossary of Abbreviations
      • External Publications
        • Authored Books
        • Journal Articles
        • Edited Books
        • Chapters in Edited Books
        • Policy Reports
        • Working Papers
        • Op-Eds
        • External Publications for the Year
      • Policy-relevant Articles Given RSIS Award
  • Media
      • Great Powers
      • Sustainable Security
      • Other Resource Pages
      • Media Highlights
      • News Releases
      • Speeches
      • Vidcast Channel
      • Audio/Video Forums
  • Events
  • Giving
  • Contact Us
  • instagram instagram rsis.sg
Connect

Getting to RSIS

Map

Address

Nanyang Technological University
Block S4, Level B3,
50 Nanyang Avenue,
Singapore 639798

View location on Google maps Click here for directions to RSIS

Get in Touch

    Connect with Us

      rsis.ntu
      rsis_ntu
      rsisntu
    RSISVideoCast RSISVideoCast rsisvideocast
      school/rsis-ntu
    instagram instagram rsis.sg
      RSS
    Subscribe to RSIS Publications
    Subscribe to RSIS Events

    RSIS Intranet

    S. Rajaratnam School of International Studies Think Tank and Graduate School Ponder The Improbable Since 1966
    Nanyang Technological University Nanyang Technological University

    Skip to content

     
    • RSIS
    • Publication
    • RSIS Publications
    • Global Health Security COVID-19 and Its Impact – India’s Vaccine Ambition: How Far Can It Go?
    • Annual Reviews
    • Books
    • Bulletins and Newsletters
    • Commentaries
    • Counter Terrorist Trends and Analyses
    • Commemorative / Event Reports
    • IDSS Paper
    • Interreligious Relations
    • Monographs
    • NTS Insight
    • Policy Reports
    • Working Papers
    • RSIS Publications for the Year

    Global Health Security COVID-19 and Its Impact – India’s Vaccine Ambition: How Far Can It Go?
    P. S. Suryanarayana

    06 July 2021

    download pdf
    RSIS Commentary is a platform to provide timely and, where appropriate, policy-relevant commentary and analysis of topical and contemporary issues. The authors’ views are their own and do not represent the official position of the S. Rajaratnam School of International Studies (RSIS), NTU. These commentaries may be reproduced with prior permission from RSIS and due credit to the author(s) and RSIS. Please email to Editor RSIS Commentary at [email protected].

    SYNOPSIS

    Battling the devastating second wave of COVID-19, India sought urgent help from the distant US even though China expressed neighbourly support. Delhi is seeking ‘vaccine partnership’ with the US and a new template of globalisation as an economic alternative to China’s dominance of supply chains. The unsettled China-India relationship also appears to influence Delhi’s thinking.

    Source: Unsplash

    COMMENTARY

    ON 12 JUNE 2021, India urged the Group of Seven (G7) industrialised countries to promote free trade in vaccine-related and other technologies being developed to fight the COVID-19 pandemic. At the World Trade Organisation (WTO), India and South Africa had earlier proposed a waiver of the relevant intellectual property rights (IPR).

    Such an IPR waiver might enable competent countries to produce qualitative COVID-19 vaccines, enlarging the global base for COVID-19 relief. This could arguably be the first step towards a new globalisation template. Following a US-led tele-conference among seven Indo-Pacific countries in May 2020, India had said all those seven states “underlined the need for a new template of globalisation” to overcome COVID-19.

    Why the Push for a New Globalisation Template

    The crux of the reported Indo-Pacific consensus in 2020 calling for a new globalisation template was to reduce the world’s reliance on the perceived Chinese monopoly over numerous industrial and other supply chains. Delhi therefore expects the US to become a source of critical help to roll back the pandemic’s second wave in India in 2021.

    Indian External Affairs Minister S. Jaishankar visited Washington in May 2021, seeking to forge a US-India vaccine partnership. Responding on 3 June, America announced that it would supply its COVID-19 vaccines to India under President Joe Biden’s “Strategy for Global Vaccine Sharing”.

    China responded by matching this. The Chinese ambassador to India, Sun Weidong portrayed on 8 June how his country was second to none in helping India fight the pandemic. Tapping the Chinese economy for this purpose “fully shows that the industrial and supply chains with China’s participation are highly effective and reliable”, he emphasised.

    Sun’s apparent aim was to counter the idea of a multi-national network of resilient supply chains as an alternative to those already radiating from China. But, in India’s view, the real issue is the lack of political trust when it comes to China, given Beijing’s growing control over a wide range of supply chains.

    Delicate Situation

    In light of Delhi’s concerns, Chinese President Xi Jinping messaged Indian Prime Minister Narendra Modi on 30 April that the “human race belongs to a community with a shared future”. On that basis Xi offered Modi “support and help” to fight the pandemic’s second wave.

    Xi’s intention was to show that his offer was not a cosmetic conciliatory gesture amidst the ongoing Sino-Indian military standoff. Xi made the offer despite Beijing’s “concern and regret” over the recent exclusion of Chinese telecom majors from India’s trials for its rollout of 5G knowhow and equipment.

    Chinese Foreign Minister Wang Yi telephoned his Indian counterpart Jaishankar to detail the help being offered to battle COVID-19. When Jaishankar raised the concerns of Indian entities which were already buying COVID-19 relief materials from China, Wang Yi assured “facilitation” of customs clearances and shipping logistics.

    However, with the unresolved year-long military crisis overshadowing, the pricing for Indian purchases of Chinese COVID-19 relief materials took on contentious overtones. Delhi began evaluating the risks of its over-dependence on China.

    By mid-May, Beijing’s response was that the pricing was determined by market forces and China itself had to pay high prices while fighting COVID-19 in its initial stage. For good measure, Beijing emphasised the Chinese supplies of essential raw materials for vaccine production in India over time.

    A Pharma Factory of the World?

    India is a key pharmaceutical factory of the world, including as a producer of generic vaccines. But the scale of China’s current production of COVID-19 vaccines is a new factor of relevance to India in the global pharmaceutical sector. Competitively, India has begun to seek assured supplies of raw materials from the US for the production of COVID-19 vaccines for domestic and global use.

    Some of these raw materials can be used in both civil and military sectors, making it a sensitive matter. This was evident in the Pentagon’s brief non-committal statement on US Defence Secretary Lloyd Austin’s talks with Jaishankar in May. They “discussed opportunities to deepen coordination amid the resurgence of COVID-19 cases [in India]”. No details were given.

    But Delhi needs a sustained supply of US-origin raw materials for COVID-19 vaccine production because Indian requirements to fight the pandemic have soared. Furthermore, severely affected internationally is Modi’s “Vaccine Maitri” (vaccine-borne friendship) programme of humanitarian and commercial exports.

    Indo-Pacific Hub for Vaccine Production?

    Already identified as a potential Indo-Pacific hub for COVID-19 vaccine production, India’s hope of becoming an exemplary major power depends on this niche role among other factors. On 12 March, the role was assigned to India at an online summit of the Quad – a security forum comprising the US, Japan, India and Australia.

    Under the plan, qualitative COVID-19 vaccine, based on American technologies, would be manufactured in India. Financial resources for the production and distribution in the Indo-Pacific region were also identified.

    For the Quad initiative to become fully operational, a substantive US-India vaccine partnership and a waiver of the relevant IPR would be essential. Separately, India seeks to compete with China, two of whose COVID-19 vaccines have received emergency-use listing by the World Health Organisation (WHO). A made-by-India COVID-19 vaccine is said to be awaiting WHO’s approval.

    On balance, while accepting support from the increasingly Sino-sceptic US and G7, India runs the risk of a recessed dream of becoming a global player by its own efforts. It should control and roll back the COVID-19 pandemic in the country and stabilise relations with China to stay relevant to the wider world.

    About the Author

    P S Suryanarayana is an Adjunct Senior Fellow with the S. Rajaratnam School of International Studies (RSIS), Nanyang Technological University (NTU), Singapore. He is author of ‘The Elusive Tipping Point: China-India Ties for a New Order’ (Singapore, World Scientific, 2021). This is part of a series.

    Categories: Commentaries / Country and Region Studies / Non-Traditional Security / East Asia and Asia Pacific / Global / South Asia / Southeast Asia and ASEAN

    Last updated on 08/07/2021

    comments powered by Disqus
    RSIS Commentary is a platform to provide timely and, where appropriate, policy-relevant commentary and analysis of topical and contemporary issues. The authors’ views are their own and do not represent the official position of the S. Rajaratnam School of International Studies (RSIS), NTU. These commentaries may be reproduced with prior permission from RSIS and due credit to the author(s) and RSIS. Please email to Editor RSIS Commentary at [email protected].

    SYNOPSIS

    Battling the devastating second wave of COVID-19, India sought urgent help from the distant US even though China expressed neighbourly support. Delhi is seeking ‘vaccine partnership’ with the US and a new template of globalisation as an economic alternative to China’s dominance of supply chains. The unsettled China-India relationship also appears to influence Delhi’s thinking.

    Source: Unsplash

    COMMENTARY

    ON 12 JUNE 2021, India urged the Group of Seven (G7) industrialised countries to promote free trade in vaccine-related and other technologies being developed to fight the COVID-19 pandemic. At the World Trade Organisation (WTO), India and South Africa had earlier proposed a waiver of the relevant intellectual property rights (IPR).

    Such an IPR waiver might enable competent countries to produce qualitative COVID-19 vaccines, enlarging the global base for COVID-19 relief. This could arguably be the first step towards a new globalisation template. Following a US-led tele-conference among seven Indo-Pacific countries in May 2020, India had said all those seven states “underlined the need for a new template of globalisation” to overcome COVID-19.

    Why the Push for a New Globalisation Template

    The crux of the reported Indo-Pacific consensus in 2020 calling for a new globalisation template was to reduce the world’s reliance on the perceived Chinese monopoly over numerous industrial and other supply chains. Delhi therefore expects the US to become a source of critical help to roll back the pandemic’s second wave in India in 2021.

    Indian External Affairs Minister S. Jaishankar visited Washington in May 2021, seeking to forge a US-India vaccine partnership. Responding on 3 June, America announced that it would supply its COVID-19 vaccines to India under President Joe Biden’s “Strategy for Global Vaccine Sharing”.

    China responded by matching this. The Chinese ambassador to India, Sun Weidong portrayed on 8 June how his country was second to none in helping India fight the pandemic. Tapping the Chinese economy for this purpose “fully shows that the industrial and supply chains with China’s participation are highly effective and reliable”, he emphasised.

    Sun’s apparent aim was to counter the idea of a multi-national network of resilient supply chains as an alternative to those already radiating from China. But, in India’s view, the real issue is the lack of political trust when it comes to China, given Beijing’s growing control over a wide range of supply chains.

    Delicate Situation

    In light of Delhi’s concerns, Chinese President Xi Jinping messaged Indian Prime Minister Narendra Modi on 30 April that the “human race belongs to a community with a shared future”. On that basis Xi offered Modi “support and help” to fight the pandemic’s second wave.

    Xi’s intention was to show that his offer was not a cosmetic conciliatory gesture amidst the ongoing Sino-Indian military standoff. Xi made the offer despite Beijing’s “concern and regret” over the recent exclusion of Chinese telecom majors from India’s trials for its rollout of 5G knowhow and equipment.

    Chinese Foreign Minister Wang Yi telephoned his Indian counterpart Jaishankar to detail the help being offered to battle COVID-19. When Jaishankar raised the concerns of Indian entities which were already buying COVID-19 relief materials from China, Wang Yi assured “facilitation” of customs clearances and shipping logistics.

    However, with the unresolved year-long military crisis overshadowing, the pricing for Indian purchases of Chinese COVID-19 relief materials took on contentious overtones. Delhi began evaluating the risks of its over-dependence on China.

    By mid-May, Beijing’s response was that the pricing was determined by market forces and China itself had to pay high prices while fighting COVID-19 in its initial stage. For good measure, Beijing emphasised the Chinese supplies of essential raw materials for vaccine production in India over time.

    A Pharma Factory of the World?

    India is a key pharmaceutical factory of the world, including as a producer of generic vaccines. But the scale of China’s current production of COVID-19 vaccines is a new factor of relevance to India in the global pharmaceutical sector. Competitively, India has begun to seek assured supplies of raw materials from the US for the production of COVID-19 vaccines for domestic and global use.

    Some of these raw materials can be used in both civil and military sectors, making it a sensitive matter. This was evident in the Pentagon’s brief non-committal statement on US Defence Secretary Lloyd Austin’s talks with Jaishankar in May. They “discussed opportunities to deepen coordination amid the resurgence of COVID-19 cases [in India]”. No details were given.

    But Delhi needs a sustained supply of US-origin raw materials for COVID-19 vaccine production because Indian requirements to fight the pandemic have soared. Furthermore, severely affected internationally is Modi’s “Vaccine Maitri” (vaccine-borne friendship) programme of humanitarian and commercial exports.

    Indo-Pacific Hub for Vaccine Production?

    Already identified as a potential Indo-Pacific hub for COVID-19 vaccine production, India’s hope of becoming an exemplary major power depends on this niche role among other factors. On 12 March, the role was assigned to India at an online summit of the Quad – a security forum comprising the US, Japan, India and Australia.

    Under the plan, qualitative COVID-19 vaccine, based on American technologies, would be manufactured in India. Financial resources for the production and distribution in the Indo-Pacific region were also identified.

    For the Quad initiative to become fully operational, a substantive US-India vaccine partnership and a waiver of the relevant IPR would be essential. Separately, India seeks to compete with China, two of whose COVID-19 vaccines have received emergency-use listing by the World Health Organisation (WHO). A made-by-India COVID-19 vaccine is said to be awaiting WHO’s approval.

    On balance, while accepting support from the increasingly Sino-sceptic US and G7, India runs the risk of a recessed dream of becoming a global player by its own efforts. It should control and roll back the COVID-19 pandemic in the country and stabilise relations with China to stay relevant to the wider world.

    About the Author

    P S Suryanarayana is an Adjunct Senior Fellow with the S. Rajaratnam School of International Studies (RSIS), Nanyang Technological University (NTU), Singapore. He is author of ‘The Elusive Tipping Point: China-India Ties for a New Order’ (Singapore, World Scientific, 2021). This is part of a series.

    Categories: Commentaries / Country and Region Studies / Non-Traditional Security

    Last updated on 08/07/2021

    Back to top

    Terms of Use | Privacy Statement
    Copyright © S. Rajaratnam School of International Studies. All rights reserved.
    This site uses cookies to offer you a better browsing experience. By continuing, you are agreeing to the use of cookies on your device as described in our privacy policy. Learn more
    OK
    Latest Book
    Global Health Security COVID-19 and Its Impact – India’s Vaccine Ambition: How Far Can It Go?

    SYNOPSIS

    Battling the devastating second wave of COVID-19, India sought urgent help from the distant US even though China expressed neighbourly support. Del ...
    more info